Today, the Administration released a final rule, Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals, along with an interim final rule, Most Favored Nations (MFN) Model. In response, AMCP CEO Susan A. Cantrell, RPh, CAE, released the following statement.
Supreme Court Hears Oral Arguments in California v. Texas; AMCP Submits Comments on CMS Third COVID Interim Final Rule; AMCP Submits Comments on Medicare Coverage of Innovative Technology Proposed Rule; Pharmaceutical Supply and Payment Chain Coalition Releases Principles for Safe Access to COVID-19 Vaccine; HHS Partners with Pharmacies to Distribute COVID-19 Vaccine; CMS Releases Fourth COVID-19 Interim Final Rule with Comment Period (IFC-4); Trump Administration Releases Insurance Transparency Final Rule; FDA Releases Essential Medicines under ‘Buy American’ Executive Order; Election 2020: A Biden/Harris White House, Slim Democrat House Majority, and Senate Runoff.
AMCP Submits Comments to CMS About the Part D Medication Therapy Management Program; U.S. Supreme Court Hears Arguments in the Rutledge v. Pharmaceutical Care Management Association (PCMA) Case; President Trump’s Plan to Deliver $200 Prescription Drug Discount Cards to Seniors is Delayed; FDA Releases Guidance Regarding COVID-19 Vaccines; FDA Authorizes a Point-of-care Coronavirus Antibody Test; Senate Committee Holds Hearing on Federal Response to COVID-19.
AMCP Virtual Legislative Days 2020; AMCP Sends Letter to HHS Secretary Azar on Anti-Kickback Rules Concerns; HHS Authorizes Pharmacists to Administer COVID-19 Vaccine; AMCP Submits Comments on COVID-19 Vaccine Allocation Framework; CMS Issues Proposed Rule Establishing a New Coverage Pathway for Breakthrough Devices; CMS Issues Rule Limiting Pharmacist-Administered COVID-19 Testing; President Trump Signs Drug Pricing Executive Order.
CMS Issues Request for Information on Electronic Prescribing of Controlled Substances; President Trump Signed Executive Orders on Drug Pricing; AMCP Submits Comments on Medicaid Drug Rebate Program Proposed Rule; House of Representatives Holds COVID-19 Vaccine and Coronavirus Response Hearings.
CMS Issues Proposed Rule Updating the Medicaid Drug Rebate Program; SAMHSA Publishes Final Rule Amending Substance Use Disorder Treatment Records Privacy; AMCP Joins Pharmacy Stakeholder Letter on Vaccine Administration; AMCP Signs Joint Comment Letter on Pharmacy Telehealth in Medicare.